John D. Quisel Sells 12,791 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 12,791 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,757,010.65. This trade represents a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Disc Medicine Stock Down 0.9 %

Shares of Disc Medicine stock opened at $62.95 on Friday. The business’s fifty day simple moving average is $58.50 and its 200-day simple moving average is $50.33. The firm has a market cap of $1.87 billion, a PE ratio of -15.82 and a beta of 0.76. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15. As a group, equities analysts expect that Disc Medicine, Inc. will post -4.05 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. Wedbush restated an “outperform” rating and issued a $83.00 price target on shares of Disc Medicine in a research report on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Tuesday, October 15th. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $66.00 to $110.00 in a report on Monday, November 4th. Finally, Scotiabank lifted their price target on Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $87.50.

Hedge Funds Weigh In On Disc Medicine

Hedge funds have recently made changes to their positions in the stock. Amalgamated Bank raised its position in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Disc Medicine during the 2nd quarter worth about $129,000. Quest Partners LLC acquired a new position in Disc Medicine during the 3rd quarter worth about $131,000. Finally, Quantbot Technologies LP purchased a new position in Disc Medicine during the 3rd quarter valued at about $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.